WO2009138408A3 - Methods and kits for the diagnosis of rheumatoid arthritis - Google Patents

Methods and kits for the diagnosis of rheumatoid arthritis Download PDF

Info

Publication number
WO2009138408A3
WO2009138408A3 PCT/EP2009/055731 EP2009055731W WO2009138408A3 WO 2009138408 A3 WO2009138408 A3 WO 2009138408A3 EP 2009055731 W EP2009055731 W EP 2009055731W WO 2009138408 A3 WO2009138408 A3 WO 2009138408A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
diagnosis
methods
rheumatoid arthritis
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/055731
Other languages
French (fr)
Other versions
WO2009138408A2 (en
Inventor
Jean Roudier
Isabelle Auger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to US12/989,806 priority Critical patent/US8338188B2/en
Priority to EP09745740A priority patent/EP2286233A2/en
Priority to JP2011508900A priority patent/JP5663723B2/en
Publication of WO2009138408A2 publication Critical patent/WO2009138408A2/en
Publication of WO2009138408A3 publication Critical patent/WO2009138408A3/en
Anticipated expiration legal-status Critical
Priority to US13/724,595 priority patent/US20130178388A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker- proteins like the BRAF catalytic domain that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.
PCT/EP2009/055731 2008-05-14 2009-05-12 Methods and kits for the diagnosis of rheumatoid arthritis Ceased WO2009138408A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/989,806 US8338188B2 (en) 2008-05-14 2009-05-12 Methods and kits for the diagnosis of rheumatoid arthritis
EP09745740A EP2286233A2 (en) 2008-05-14 2009-05-12 Methods and kits for the diagnosis of rheumatoid arthritis
JP2011508900A JP5663723B2 (en) 2008-05-14 2009-05-12 Methods and kits for the diagnosis of rheumatoid arthritis
US13/724,595 US20130178388A1 (en) 2008-05-14 2012-12-21 Methods and Kits for the Diagnosis of Rheumatoid Arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08305167.2 2008-05-14
EP08305167 2008-05-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/724,595 Division US20130178388A1 (en) 2008-05-14 2012-12-21 Methods and Kits for the Diagnosis of Rheumatoid Arthritis

Publications (2)

Publication Number Publication Date
WO2009138408A2 WO2009138408A2 (en) 2009-11-19
WO2009138408A3 true WO2009138408A3 (en) 2010-01-14

Family

ID=39643997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/055731 Ceased WO2009138408A2 (en) 2008-05-14 2009-05-12 Methods and kits for the diagnosis of rheumatoid arthritis

Country Status (4)

Country Link
US (2) US8338188B2 (en)
EP (1) EP2286233A2 (en)
JP (1) JP5663723B2 (en)
WO (1) WO2009138408A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336769A1 (en) * 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
AU2012253691B2 (en) * 2011-05-10 2016-05-19 Société des Produits Nestlé S.A. Methods for diagnosing degenerative joint disease
EP2527841A1 (en) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
US10060911B2 (en) * 2011-08-19 2018-08-28 Protagen Aktiengesellschaft Method for diagnosis of high-affinity binders and marker sequences
EP2644704A1 (en) * 2012-03-27 2013-10-02 Protagen AG Marker sequences for rheumatoid arthritis
WO2013170994A1 (en) 2012-03-27 2013-11-21 Protagen Ag Marker sequences for rheumatoid arthritis
JPWO2015016096A1 (en) * 2013-07-31 2017-03-02 国立大学法人京都大学 Method for determining autoimmune arthritis and screening method for autoimmune arthritis-inducing T cell activation inhibitor
BR112017008877A2 (en) 2014-10-29 2018-07-03 10X Genomics Inc methods and compositions for targeting nucleic acid sequencing
EP3316878B1 (en) 2015-07-03 2022-02-09 Catrina, Anca Methods and compounds for the alleviation of pain
EP3436828A1 (en) 2016-04-02 2019-02-06 Protagen AG Marker sequences for rheumatoid arthritis
CN106950365B (en) * 2017-02-15 2018-11-27 中国医学科学院北京协和医院 A kind of RA diagnosis marker of ACPA feminine gender and its application
US10742435B2 (en) 2017-06-29 2020-08-11 Google Llc Proactive provision of new content to group chat participants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
DK1721162T3 (en) * 2004-02-27 2008-12-15 Hoffmann La Roche Method to assess rheumatoid arthritis by measuring anti-CCP and serum amyloid A
JP4411416B2 (en) * 2004-11-09 2010-02-10 独立行政法人理化学研究所 Use of anti-citrullinated collagen and type I collagen in the diagnosis of rheumatoid arthritis
WO2007123976A2 (en) * 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE VRIES-BOUWSTRA J K ET AL: "Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.", ARTHRITIS AND RHEUMATISM MAY 2008, vol. 58, no. 5, May 2008 (2008-05-01), pages 1293 - 1298, XP002498678, ISSN: 0004-3591 *
FENSTERLE JOACHIM ET AL: "B-Raf specific antibody responses in melanoma patients", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 12 September 2004 (2004-09-12), pages 62, XP021004664, ISSN: 1471-2407 *
KIM TAE YONG ET AL: "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.", CLINICAL ENDOCRINOLOGY SEP 2006, vol. 65, no. 3, September 2006 (2006-09-01), pages 364 - 368, XP002498677, ISSN: 0300-0664 *
SUZUKI A ET AL: "Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 34, no. 4, 1 August 2003 (2003-08-01), pages 395 - 402, XP002979063, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
JP5663723B2 (en) 2015-02-04
US8338188B2 (en) 2012-12-25
JP2011521216A (en) 2011-07-21
EP2286233A2 (en) 2011-02-23
WO2009138408A2 (en) 2009-11-19
US20110065609A1 (en) 2011-03-17
US20130178388A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
WO2009138408A3 (en) Methods and kits for the diagnosis of rheumatoid arthritis
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2011100708A3 (en) Assay card for sample acquisition, treatment and reaction
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
EP4449978A3 (en) Tissue-integrating sensors
WO2009102421A3 (en) Targeted therapeutics based on engineered proteins that bind egfr
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
WO2016013940A3 (en) Novel test for microbial blood infections
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
AU2012262364A8 (en) Systems and methods for genetic and biological analysis
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
EP2464751A4 (en) Methods, primers, probes and kits useful for the detection of braf mutations
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2008074029A3 (en) Protein profile for osteoarthritis
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2014008312A3 (en) Primers, assays and methods for detecting an e. coli subtype
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
HK1207887A1 (en) Assays, methods and apparatus for assessing rna disruption
WO2006036175A3 (en) Wnt proteins and detection and treatment of cancer
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2006036179A3 (en) Frizzled proteins and detection and treatment of cancer
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2009082445A3 (en) Novel devices for the detection of the presence and/or activity of proteases in biological samples
IN2012DN04381A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745740

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2009745740

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009745740

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011508900

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12989806

Country of ref document: US